Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Incidence of Radiologically Isolated Syndrome: A Population-Based Study.
[Effects of caffeine citrate on myelin basic protein in neonatal rats with hypoxic-ischemic brain damage].
Fingolimod attenuates splenocyte-induced demyelination in cerebellar slice cultures.
Aggregation Kinetics for IgG1-Based Monoclonal Antibody Therapeutics.
Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13.
The possible efficacy of artichoke in fluconazole related hepatotoxicity.
Participation of interleukin 17A in neuroimmune interactions.
Histological correlation of diffusional kurtosis and white matter modeling metrics in cuprizone-induced corpus callosum demyelination.
The effect of group psycho-education program on the burden of family caregivers with multiple sclerosis patients in Isfahan in 2013-2014.
SOX17 is expressed in regenerating oligodendrocytes in experimental models of demyelination and in multiple sclerosis.
The complex immunology of multiple sclerosis.
[Cognitive deficits and dementia in patients with multiple sclerosis: status quo and open questions].
Initial investigation of the blood-brain barrier in MS lesions at 7 tesla.
Laparoscopic implantation of neuromodulators for treating urinary dysfunctions and improving locomotion in multiple sclerosis patients.
Correction: Comparative Study on the Therapeutic Potential of Neurally Differentiated Stem Cells in a Mouse Model of Multiple Sclerosis.
Patient with Neuromyelitis Optica Spectrum Disorder Combined with Sjögren's Syndrome Relapse Free Following Tacrolimus Treatment.
Multiple sclerosis drugs: how much bang for the buck?
Association of SNPs of CD40 Gene with Multiple Sclerosis in Russians.
Silent aspiration and recovery from Dysphagia in a case of bickerstaff brainstem encephalitis.
Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab.
From the Cajal alumni Achúcarro and Río-Hortega to the rediscovery of never-resting microglia.
MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: Yes.
Iron deposition in the precentral grey matter in patients with multiple sclerosis: A quantitative study using susceptibility-weighted imaging.
A Model of Population and Subject (MOPS) Intensities with Application to Multiple Sclerosis Lesion Segmentation.
Cladribine in multiple sclerosis: pitfalls in a new treatment landscape.

Pages